The stock will trade on pipeline catalysts, not quarterly financials. Key events to watch: ASCO presentation of OP-3136 data (late May 2026) and top-line OPERA-01 Phase 3 data (fall 2026). The $505M cash position funds operations through these milestones. No revenue or earnings guidance was provided.
Price Chart
Executive Summary
Olema Pharmaceuticals reported Q1 2026 financial results, with a net loss of $53.1M (vs $30.4M in Q1 2025) driven by increased R&D spending on late-stage trials. The company ended the quarter with $505.3M in cash and highlighted upcoming catalysts: top-line Phase 3 OPERA-01 data expected this fall and initial Phase 1 data for OP-3136 at ASCO. As a pre-revenue clinical-stage biotech, the widening loss was expected and the cash runway supports operations through key data readouts.
Key Financial Metrics
Key Facts
- Net loss for Q1 2026 was $53.1M, compared to $30.4M in Q1 2025
- Cash, cash equivalents, and marketable securities were $505.3M as of March 31, 2026
- GAAP R&D expenses were $49.2M in Q1 2026 vs $30.6M in Q1 2025
- GAAP G&A expenses were $8.8M in Q1 2026 vs $4.2M in Q1 2025
- Top-line data from Phase 3 OPERA-01 trial of palazestrant expected in fall 2026
- Initial Phase 1 clinical data for OP-3136 to be presented at ASCO in May 2026
- No revenue reported; company is a clinical-stage biopharmaceutical firm
Financial Impact
Net loss increased by $22.7M YoY to $53.1M; cash burn rate increased as R&D spending rose 61% to $49.2M
Risk Factors
- Phase 3 OPERA-01 trial failure would be a significant negative catalyst
- Cash burn rate is accelerating as R&D spending increases
- No approved products or revenue; fully dependent on clinical trial success
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-218142 |
| Document: olma-ex99_1.htm | 0001193125-26-218142 |
| Document: 0001193125-26-218142-index-headers.html | 0001193125-26-218142 |
| Document: 0001193125-26-218142-index.html | 0001193125-26-218142 |
| Document: 0001193125-26-218142.txt | 0001193125-26-218142 |
| 8-K Data (Synthetic) | 0001193125-26-218142 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 8-K | $10.43 $10.36 | ▼ −0.67% | ▲ +0.39% | $8.23 (−21.14%) |
Aug 10, 2026 7w ago | Press Release | $10.43 $10.36 | ▼ −0.67% | ▲ +0.39% | $8.23 (−21.14%) |
Aug 9, 2026 7w ago | Institutional Cluster | $11.94 $10.99 | ▲ +8.00% | ▲ +7.08% | $8.23 (+31.11%) |
May 26, 2026 18w ago | 8-K | $13.55 $11.46 | ▼ −15.42% | ▼ −13.48% | $8.23 (−39.30%) |
May 26, 2026 18w ago | Press Release | $13.55 $11.46 | ▼ −15.42% | ▼ −13.48% | $8.23 (−39.30%) |
May 21, 2026 19w ago | 8-K | $13.68 $10.19 | ▼ −25.51% | ▼ −24.10% | $8.23 (−39.88%) |
May 21, 2026 19w ago | Press Release | $13.68 $10.19 | ▼ −25.51% | ▼ −24.10% | $8.23 (−39.88%) |
May 12, 2026 20w ago | 8-K | $13.97 $9.82 | ▼ −29.71% | ▼ −27.98% | $8.23 (−41.12%) |
May 12, 2026 20w ago | Press Release | $13.97 $9.82 | ▼ −29.71% | ▼ −27.98% | $8.23 (−41.12%) |
Apr 29, 2026 22w ago | DEFA14A | $14.41 $13.19 | ▼ −8.47% | ▼ −13.69% | $8.23 (−42.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access